196 related articles for article (PubMed ID: 15548771)
1. Merck's recall of rofecoxib--a strategic perspective.
Oberholzer-Gee F; Inamdar SN
N Engl J Med; 2004 Nov; 351(21):2147-9. PubMed ID: 15548771
[No Abstract] [Full Text] [Related]
2. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Meyer CH
Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
[No Abstract] [Full Text] [Related]
3. Balancing risks and benefits in pain medicine: wither Vioxx.
Gallagher RM
Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
[No Abstract] [Full Text] [Related]
4. Implications of the rofecoxib trials.
Kozma CM
Manag Care Interface; 2005 Oct; 18(10):61-2. PubMed ID: 16265937
[No Abstract] [Full Text] [Related]
5. Rofecoxib (Vioxx) voluntarily withdrawn from market.
Sibbald B
CMAJ; 2004 Oct; 171(9):1027-8. PubMed ID: 15505253
[No Abstract] [Full Text] [Related]
6. A bitter pill for one Merck critic.
McLean B
Fortune; 2004 Dec; 150(12):58. PubMed ID: 15617422
[No Abstract] [Full Text] [Related]
7. FDA warns Merck over its promotion of rofecoxib.
Josefson D
BMJ; 2001 Oct; 323(7316):767. PubMed ID: 11588068
[No Abstract] [Full Text] [Related]
8. The right pill for growth. The high cost of developing blockbuster drugs forces big makers into bigger mergers.
Fischer JS
US News World Rep; 1999 Nov; 127(19):56. PubMed ID: 10623304
[No Abstract] [Full Text] [Related]
9. Drug pullout. Massive recall of Vioxx poses logistical problems.
Becker C
Mod Healthc; 2004 Oct; 34(42):17. PubMed ID: 15552189
[No Abstract] [Full Text] [Related]
10. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical manufacturers ... leaving tradition behind and forging new managed care alliances.
Barnett AA
State Health Care Am; 1995; ():41-6. PubMed ID: 10168072
[No Abstract] [Full Text] [Related]
12. Out of sight. Pharmaceutical industry temporarily replaces hospitals as target.
McLaughlin N
Mod Healthc; 2004 Oct; 34(42):26. PubMed ID: 15552190
[No Abstract] [Full Text] [Related]
13. [One man's loss is another man's gain].
Laake JH
Tidsskr Nor Laegeforen; 2004 Dec; 124(23):3095. PubMed ID: 15586198
[No Abstract] [Full Text] [Related]
14. Merck's actions surrounding Vioxx.
Heinley M
PLoS Med; 2006 Jun; 3(6):e286; author reply e285. PubMed ID: 16789808
[No Abstract] [Full Text] [Related]
15. Clinical research: outlook from industry.
Echols R
Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
[No Abstract] [Full Text] [Related]
16. Learning the value of drugs--is rofecoxib a regulatory success story?
Eisenberg RS
N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
[No Abstract] [Full Text] [Related]
17. Merck to pay $5bn in rofecoxib claims.
Charatan F
BMJ; 2007 Nov; 335(7628):1011. PubMed ID: 18006982
[No Abstract] [Full Text] [Related]
18. Merck pays $1bn penalty in relation to promotion of rofecoxib.
Tanne JH
BMJ; 2011 Nov; 343():d7702. PubMed ID: 22123916
[No Abstract] [Full Text] [Related]
19. What does R&D really cost?
Huff B
GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
[No Abstract] [Full Text] [Related]
20. Vioxx may go back on sale after scraping past FDA panel.
Wadman M
Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
[No Abstract] [Full Text] [Related]
[Next] [New Search]
